All In Biotech

Drug Trial Radar · NCT00994149

Diazoxide In the Management Of Hypoglycemic Neonates

Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation

Last checked: Nov 20, 2026Latest source record: Oct 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 2009

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
University of SaskatchewanAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 14, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, up to 12 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Diazoxide is an oral hyperglycemic medication. Diazoxide has been proven effective for treating hypoglycemia in infants and children with some types of persistent hyperinsulinemic hypoglycemia. The mechanism of action results in decreased insulin secretion. One of the causes of hypoglycemia in infants of diabetic mothers occurs due to a transient hyperinsulinemic state postnatally. The investigators have clinical experience and success using diazoxide in their unit for patients with hypoglycemia not adequately managed with intravenous (iv) dextrose and enteral supplementation. In this randomized controlled study the investigators expect that by using diazoxide as the initial treatment for infants of diabetic mothers with asymptomatic hypoglycemia (blood glucose of 2.5 to 2.0mmol/L), the investigators will be able to decrease the number of infants requiring an intravenous by at least thirty percent.

Conditions

  • Infant, Newborn, Diseases
  • Pregnancy in Diabetics
  • Infant, Diabetic Mother
  • Hypoglycemia
  • Infant, Large for Gestational Age

Interventions

  • DiazoxideDrug

    10mg/kg/d divide every 8 hours

  • Ora-plusDrug

    placebo, give every 8 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood glucose measurement less than 2.0mmol/LTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.